Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cabozantinib-s-malate
Find trials that include:  Any drugs shown
Results 1-25 of 25 for your search:
Start Over
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: XL184-309, NCI-2013-02092, NCT01908426
Cabozantinib-S-Malate, Docetaxel, and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0204, NCI-2013-01554, 120204, P11901, P9243_A21PAMDREVW01, 9243, NCT01683994
Cabozantinib-S-Malate in Treating Patients with Recurrent or Refractory Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-240, NCI-2013-01098, NCT01866293
Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-208, NCI-2011-03519, NCT01441947
Cabozantinib-s-Malate in Treating Patients with Advanced Pancreatic Neuroendocrine or Carcinoid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-274, NCI-2012-00539, NCT01466036
Cabozantinib-s-malate in Treating Patients with Metastatic or Refractory Solid Tumors and Bone Metastases
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-091, NCI-2012-00991, NCT01588821
Magnetic Resonance Imaging in Measuring Efficacy of Cabozantinib on Bone Metastases in Patients With Hormone Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: Not specified
Trial IDs: 12-1031, NCI-2012-00677, NCT01599793
Cabozantinib-S-Malate and Hormone Therapy in Treating Patients with Previously Untreated Androgen-Dependent Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2012-0252, NCI-2014-00934, NCI-2014-00158, NCT01630590
Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-097, NCI-2012-01187, NCT01639508
Cabozantinib-S-Malate in Treating Patients with Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0205, NCI-2013-01555, 120205, 12-C-0205J, P11900, 9236, NCT01688999
Cabozantinib-S-Malate in Treating Patients with Refractory Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0044, NCI-2012-03124, 09-25-0099, 121088, 130044, P121088, P9284_A07PAMDREVW01, 9284, NCT01755195
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12154, NCI-2013-00554, 2012C0101, RU241210I, 9312, NCT01811212
Cabozantinib-S-Malate Compared with Temozolomide or Dacarbazine in Treating Patients with Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091201, NCI-2013-00821, CALGB-A091201, NCT01835145
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: CABONE, NCI-2014-01927, 9620, NCT02243605
Cabozantinib S-malate with or without Trastuzumab in Treating Patients with Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-359, NCI-2014-02365, NCT02260531
Cabozantinib-S-Malate in Treating Patients with Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG GY-001, NCI-2014-02411, NCT02315430
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHL-086, NCI-2013-00890, NCT01815151, 9322, NCT01935934
Cabozantinib-s-malate in Treating Patients with Relapsed or Refractory Multiple Myeloma with Bone Disease
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-005, NCI-2012-01143, NCT01582295
Cabozantinib and Gemcitabine Hydrochloride in Treating Patients with Advanced or Recurrent Pancreatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2011-105, NCI-2012-01910, 2011.105, Ame00047004, HUM00062927, HUM00062927_XL184, HUM 62927, NCT01663272
Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-087, NCI-2013-00740, NCT01822522
Cabozantinib-S-Malate in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-363, NCI-2014-00084, NCT01961765
Cabozantinib-S-Malate and Panitumumab in Treating Patients with Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049983, NCI-2014-01160, NCT02008383
Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7819, NCI-2012-01898, NCT01703065
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Merkel Cell Carcinoma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 13-490, NCI-2014-00941, NCT02036476
Cabozantinib-s-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0081, NCI-2014-02607, NCT02302833
Start Over